What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?

Topics: Gynecologic Cancers • Endometrial Cancer • Medical Oncology • ASCO Journal Club • Journal Club ft. NEJM publications • Gynecologic Oncology

Are there certain patient subgroups for whom you would use the IO+PARPi?

Is there data from DUO-E regarding BRCA status and its potential impact on outcomes?

Answer from: at Community Practice

The results of DUO-E are very exciting and will serve a number of purposes. I was encouraged to continue to see that the combo of chemo IO performed better than chemo alone confirming the class effect that was seen in GY018 and RUBY. I wish there was a pre-planned comparison of the chemo/IO/Olaparib...

Comments

Medical Oncologist at Florida Cancer Specialists
The pace of research and availability of new drugs...

Answer from: at Community Practice

Based on the results of the primary objectives of DUO-E, I would only consider chemo+durva+olaparib in the pMMR patient however, I do not truly know the benefit of adding olaparib to IO in this patient population. I would like to see trials designed to compare chemo+IO versus chemo+IO+olaparib in th...

Related Questions